Modified GRF (1-29) is a 29-amino-acid peptide that copies the active front end of human growth-hormone-releasing hormone (GHRH). Natural GHRH is a 44-residue hormone made in the hypothalamus; researchers found decades ago that the first 29 amino acids carry essentially all of the signal that tells the pituitary to release growth hormone. That 1-29 fragment is the molecule marketed in medicine as sermorelin.
The "modified" version swaps four amino acids in that fragment. Per the Wikipedia summary of the chemistry) and the underlying GRF-analog patent literature, the changes are D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. Each swap does a specific job: the D-Ala at position 2 blocks the enzyme dipeptidyl peptidase-4 (DPP-4) from clipping the peptide in half, while the others cut down on oxidation and isomerization during storage and in plasma. Work on DPP-4 cleavage of position-2 GRF analogs is documented in the primary enzymology literature. The practical result: native GRF (1-29) survives under 10 minutes in circulation, and the tetrasubstituted version lasts at least about 30 minutes.
If the name "CJC-1295 without DAC" sounds familiar, that is the same molecule. CJC-1295 with DAC adds a drug affinity complex, a maleimide linker that bonds to circulating albumin and stretches the half-life to several days. Remove that linker and you are left with Modified GRF (1-29), which gives a short pulse rather than a sustained elevation.
How it is supposed to work
Like GHRH itself, Modified GRF (1-29) binds the GHRH receptor on the anterior pituitary and prompts a burst of growth hormone, which in turn raises IGF-1. Because the no-DAC form clears quickly, the proposed appeal is a pulse that resembles the body's own rhythm rather than a flat, round-the-clock signal.
What the research actually shows
This is the honest part. There are almost no published human trials on the no-DAC molecule by itself. The substantive clinical data belongs to its relatives:
- Sermorelin (plain GRF 1-29) was FDA-approved in 1997 as Geref for diagnosing and treating growth hormone deficiency in children, then withdrawn from the market for commercial reasons in 2008. It is no longer an FDA-approved product, though compounding pharmacies still prepare it.
- CJC-1295 with DAC was tested in healthy adults by Teichman and colleagues (J Clin Endocrinol Metab, 2006). Single subcutaneous doses raised mean GH 2- to 10-fold for six or more days and IGF-1 by 1.5- to 3-fold for 9-11 days, with no serious adverse reactions reported. That study covers the long-acting DAC form, not the no-DAC peptide.
So claims about Modified GRF (1-29) lean on pharmacological reasoning and on data from these adjacent compounds. There is no large body of trial evidence on safety, dosing, or long-term effects of the no-DAC version in people.
Regulatory and anti-doping status
Modified GRF (1-29) is not an approved drug. It is sold as a research chemical, labeled research use only and not for human consumption. In sport it is banned: the WADA Prohibited List places GHRH and its analogs and growth-hormone secretagogues under section S2, prohibited at all times, so any athlete in a tested pool who uses it commits a doping violation.
The buyer-quality angle
Because there is no pharmaceutical manufacturer standing behind this peptide, what ends up in a vial depends entirely on the seller. Independent third-party testing is the only real check. A useful certificate of analysis should confirm both identity and purity, typically by mass spectrometry plus HPLC, and ideally come from a lab unaffiliated with the vendor. Modified GRF (1-29) and full CJC-1295 differ only by that albumin linker, and short peptides are easy to mislabel or under-fill, so a current, matching COA tied to the specific lot matters more here than usual.
Nothing above is medical, dosing, or efficacy advice. It is a summary of what public sources document about the compound.